34528-67-1

Basic information

• Product Name: 6-Methyl-isoquinoline
• Synonyms: Isoquinoline, 6-Methyl-, radical ion(1-) (9CI);6-Methylisoquinoline(WXC01979)
• CAS NO: 34528-67-1
• Molecular Formula: C10H9N
• Molecular Weight: 143.18516
• Mol File: 34528-67-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-Methyl-isoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Methyl-isoquinoline(34528-67-1)
• EPA Substance Registry System: 6-Methyl-isoquinoline(34528-67-1)

Safety Data

• Hazardous Substances Data: 34528-67-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-Methyl-isoquinoline is used as an intermediate in the production of pharmaceuticals for its potential anti-inflammatory and anticancer properties. Its unique structure allows it to be a promising candidate for the development of new drugs.
Used in Dye Industry:
6-Methyl-isoquinoline is used as a building block in the synthesis of dyes, contributing to the creation of a variety of colorants for different applications.
Used in Organic Synthesis:
6-Methyl-isoquinoline is utilized as a key component in organic synthesis, enabling the development of new chemical compounds and materials.
Used in Catalyst Development:
6-Methyl-isoquinoline has been investigated as a potential ligand for metal catalysts in organic reactions, which could enhance the efficiency and selectivity of various chemical processes.
Used in Biological Imaging Studies:
6-Methyl-isoquinoline has been employed as a fluorescent tracer, aiding researchers in visualizing and studying biological processes and structures.
Overall, 6-Methyl-isoquinoline is a valuable chemical compound with diverse applications across multiple industries, including pharmaceuticals, dyes, organic synthesis, catalyst development, and biological imaging.

Upstream product

• 104-87-0 4-methyl-benzaldehyde 
• 645-36-3 2,2-diethoxy-ethanamine 
• 54879-84-4 2-(4-methylbenzylamino)acetaldehyde dimethyl acetal 
• 1122-62-9 2-acetylpyridine 
• 34784-05-9 6-bromo-isoquinoline 
• 22483-09-6 2,2-dimethoxyethylamine 
• 54879-70-8 (2,2-Dimethoxy-ethyl)-[1-p-tolyl-meth-(Z)-ylidene]-amine 
• 541-41-3 chloroformic acid ethyl ester 
• 54879-40-2 N-(2,2-Dimethoxy-ethyl)-4-methyl-N-(4-methyl-benzyl)-benzenesulfonamide 
• 86401-98-1 N-(tert-butyl)-N-(4-methyl-benzylidene)-amine 
• 84900-33-4 2,4,6-Trimethyl-benzenesulfonate2-amino-6-methyl-isoquinolinium; 
• 20232-11-5 6-methyl-1H-indene 

Downstream Products

• 131002-10-3 6-methyl-2H-isoquinolin-1-one 
• 1093100-17-4 4-(5-(3-(9-(4-methoxybenzyl)-9H-purin-6-yl)pyridin-2-ylamino)-6-methylisoquinolin-1-ylamino)benzonitrile 
• 1093101-70-2 N₁-((R)-1-(4-chlorophenyl)ethyl)-6-methyl-N₅-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)pyridin-2-yl)isoquinoline-1,5-diamine 
• 1093101-60-0 5-(3-(9-(4-methoxybenzyl)-9H-purin-6-yl)pyridin-2-yloxy)-N-(4-chlorophenyl)-6-methylisoquinolin-1-amine 
• 1093100-23-2 N₅-(3-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)pyridin-2-yl)-6-methyI-N₁-(3-(trifluoromethyl)phenyl)isoquinoIin-1,5-diamine 
• 1093100-63-0 N₅-(3-(9H-purin-6-yl)pyridin-2-yl)-N₁-((R)-1-(4-chlorophenyl)ethyl)-6-methylisoquinoline-1,5-diamine 
• 1093100-18-5 4-(5-(3-(9H-purin-6-yl)pyridin-2-ylamino)-6-methylisoquinolin-1-ylamino)benzonitrile 
• 1093100-53-8 4-(5-(3-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)pyridin-2-ylamino)-6-methylisoquinolin-1-ylamino)benzonitrile 
• 1093100-22-1 4-(5-(3-(5H-pyrrolo[3,2-d]pyrimidin-4-yl)pyridin-2-ylamino)-6-methylisoquinolin-1-ylamino)benzonitrile 
• 1093101-58-6 5-(3-(9-(4-methoxybenzyl)-9H-purin-6-yl)pyridin-2-yloxy)-6-methylisoquinolin-1(2H)-one 
• 1093100-24-3 5-(3-(9H-purin-6-yl)pyridin-2-yloxy)-N-(4-chlorophenyl)-6-methylisoquinolin-1-amine 
• 1093101-59-7 5-(3-(9-(4-methoxybenzyl)-9H-purin-6-yl)pyridin-2-yloxy)-1-chloro-6-methylisoquinoline 
• 1093101-68-8 (R)-N-(1-(4-chlorophenyl)ethyl)-6-methyl-5-nitroisoquinolin-1-amine 
• 1093101-45-1 4-(6-methyl-5-nitroisoquinolin-1-ylamino)benzonitrile 

Relevant articles and documents

Synthesis and properties of novel stilbazolium analogues as second-order nonlinear optical chromophores

This study synthesized a series of methoxystilbazolium analogues with π-conjugation extended by attaching a fused aromatic ring, i.e., 6-styrylisoquinolinium and 4-[2-(2-naphthyl)ethenyl]pyridinium derivatives with methoxy substituents. We evaluated their transition energies (EegS) and second-order hyperpolarizabilities (βs) experimentally using their absorption spectra and a hyper-Rayleigh scattering measurement, respectively. Subsequently, we calculated βs using the MOPAC PM3 method. These values were compared with those of 4-[4-(4-methoxyphenyl)-1,3-butadienyl]pyridinium derivative, which is a stilbazolium analogue with π-conjugation that is simply extended by an increase of the double-bond number between two aromatic rings. This study clarified that the fused-ring systems possess large βs, irrespective of their relatively short absorption wavelengths, compared to the double-bond elongation system.

Cu(II)-Catalyzed Construction of Heterobiaryls using 1-Diazonaphthoquinones: A General Strategy for the Synthesis of QUINOX and Related P,N Ligands

An efficient and straightforward method was developed for the synthesis of heterobiaryls using easily available N-oxides and diazonaphthoquinones under cheap Cu(II) catalysis. The developed method offered QUINOX and related congeners in a simple manner. A wide scope of important heterobiaryls was achieved with high site selectivity. The synthesized naphthols were transformed into the privileged related P,N ligands. Suitable resolution methods can directly afford the corresponding axially chiral heterobiaryls.

Pd-Catalyzed Alkylation of (Iso)quinolines and Arenes: 2-Acylpyridine Compounds as Alkylation Reagents

The first Pd-catalyzed alkylation of (iso)quinolines and arenes is reported. The readily available and bench-stable 2-acylpyridine compounds were used as an alkylation reagent to form the structurally versatile alkylated (iso)quinolines and arenes. The method affords a convenient pathway for the introduction of alkyl groups into organic molecules.

ISOQUINOLINE-5-CARBOXAMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE

A compound selected from the group consisting of an isoquinoline-5-carboxamide derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate and a solvate thereof is effective for the prevention or treatment of diseases associated with abnormal cell growth, which are caused by abnormal activation of a protein kinases.

ISOQUINOLINE-5-CARBOXAMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE

A compound selected from the group consisting of an isoquinoline-5-carboxamide derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate and a solvate thereof is effective for the prevention or treatment of diseases associated with abnormal cell growth, which are caused by abnormal activation of a protein kinases.

THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES

Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.

THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES

Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases

Selective inhibitors of the mutant B-Raf pathway: Discovery of a potent and orally bioavailable aminoisoquinoline

The discovery and optimization of a novel series of aminoisoquinolines as potent, selective, and efficacious inhibitors of the mutant B-Raf pathway is presented. The N-linked pyridylpyrimidine benzamide 2 was identified as a potent, modestly selective inhibitor of the B-Raf enzyme. Replacement of the benzamide with an aminoisoquinoline core significantly improved kinase selectivity and imparted favorable pharmacokinetic properties, leading to the identification of 1 as a potent antitumor agent in xenograft models. 2009 American Chemical Society.

RAF KINASE MODULATORS AND METHODS OF USE

The present invention comprises a new class of compounds capable of modulating the activity of Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula (I) wherein each of A1, A2, A3, A4, A5, A6, A7, A8, A9, bond B, X, rings Z1 and Z2, R1 and R3 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.

NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention comprises a new class of compounds capable of modulating Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have Formula (I) wherein R1 is Formula (II), (III) or (IV) and A1, A2, A3, A4, X, Z, Z', R1, R2, R3, R4, R5 and R6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.